Pancreatic protease inhibition during shock attenuates cell activation and peripheral inflammation

Journal of Vascular Research

Volumn 39, Issue 4, 2002, Pages 320-329

  Fitzal, Florian ^a,b   Delano, Frank A ^a   Young, Corey ^a   Rosario, Henrique S ^a,c   Schmid Schönbein, Geert W ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Cell death; Intestine; Leukocyte activation; Microcirculation; Muscle injury; Systemic inflammatory response syndrome

Indexed keywords

GABEXATE MESILATE; INTERLEUKIN 8; PROTEINASE; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL ACTIVATION; CELL DEATH; CONTROLLED STUDY; CREMASTER MUSCLE; ENZYME INHIBITION; HYPOTENSION; INFLAMMATION; INTESTINE; INTESTINE INJURY; INTESTINE ISCHEMIA; INTESTINE MUCOSA; LAVAGE; MALE; MICROSCOPY; MULTIPLE ORGAN FAILURE; NONHUMAN; PANCREAS; PLASMA; PRIORITY JOURNAL; RAT; SHOCK; SUPERIOR MESENTERIC ARTERY OBSTRUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ABDOMINAL MUSCLES; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CELL DEATH; ENDOPEPTIDASES; INFLAMMATION; INFLAMMATION MEDIATORS; INTESTINES; ISCHEMIA; MALE; MULTIPLE ORGAN FAILURE; PANCREAS; PROTEASE INHIBITORS; RATS; RATS, WISTAR; SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036373606     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065544     Document Type: Article

References (34)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients
2. Anti-inflammatory therapies to treat sepsis and septic shock. A reassessment
3. Strategies for the treatment of sepsis
4. A review of septic shock
5. Why sepsis trials fail
6. Mechanisms and consequences of cell activation in the microcirculation
7. Transformation of neutrophils as indicator of irreversibility in hemorrhagic shock
8. The pancreas as a source of cardiovascular cell activating factors
9. Pancreatic enzymes and microvascular cell activation in multiorgan failure
10. Gut ischemia and mesenteric synthesis of inflammatory cytokines after hemorrhagic or endotoxin shock
11. Mechanism of action of bacterial endotoxin
12. Graded enterectomy in Escherichia coli shock
13. Generation of in vivo activating factors in the ischemic intestine by pancreatic enzymes
14. Protease inhibition in the intestinal lumen: Attenuation of systemic inflammation and early indicators of multiple organ failure in shock
15. Plasma activation during splanchnic arterial occlusion shock
16. Biologische funktionen von proteinasen in ihrer inhibition
17. Pharmakologische grundlagen zur therapeutischen anwendbarkeit von gabexat mesilate (FOY)
18. An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy
19. The microvasculature in skeletal muscle. III. Venous network anatomy in normotensive and spontaneously hypertensive rats
20. Spatial and temporal correlation between leukocyte behavior and cell injury in postischematic rat skeletal muscle
21. Factors larger than 100 kD in posthemorrhagic shock mesenteric lymph are toxic for endothelial cells
22. The gut: A cytokine-generating organ in systemic inflammation?
23. Effect of intestinal exclusion in Escherichia coli endotoxin shock
24. Pancreatic proteases and oxygen-derived free radicals in acute ischemic enteropathy
25. The protective effect of intraluminal glucose as energy substrate
26. Regulatiion of tissue injury responses by the exposure of matricryptic sites within extra-cellular matrix molecules
27. The pathophysiologic role of myocardial depressant factor as a mediator of circulatory shock
28. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation
29. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes
30. Inhibitory effect of a synthetic protease inhibitor (gabexate mesilate) in the respiratory burst oxidase in human neutrophils
31. Effect of gabexate mesilate (FOY), a drug for serine proteinase-mediated diseases, on nitric oxide pathway
32. Mechanisms for blockade of in vivo activator production in the ischemic intestine and multi-organ failure
33. Gut derived mesenteric lymph but not portal blood increases endothelial cell permeability and promotes lung injury after hemorrhagic shock